Abstract PS5-04-02: Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-positive metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Mount Sinai Hospital, AstraZeneca (Canada), EVERSANA (Canada)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129293667
Cites:
Cited by:
Related to: